Table 3 Meta-analyses on cancer risks associated with the use of biologics to treat IMIDs
From: Cancer risk in immune-mediated inflammatory diseases (IMID)
Study | Disease | Study types included | Medication | Findings |
|---|---|---|---|---|
Bongartz et al. 2006 [119] | RA | Prosp Obs | Infliximab Adalimumab | Increased risk of malignancies |
Peyrin-Biroulet et al. 2008 [120] | Crohn’s disease | RCTs | Infliximab, adalimumab, certolizumab, CDP571 | No increase in malignancy |
Leombruno et al. 2009 [121] | RA | RCTs | Etanercept, infliximab, adalimumab | No increased risk of melanoma, lymphoma, non-lymphoma skin cancer, or cutaneous cancer + melanoma |
Bongartz et al. 2009 [122] | RA | RCTs | Etanercept for ≥ 12 weeks | Non-significant increase in cancer |
Siegel et al. 2009 [123] | Adult Crohn’s disease | RCTs | Infliximab, adalimumab, certolizumab | Increase risk of non-Hodgkin’s lymphoma |
Mariette et al. 2011 [124] | RA | Prosp Obs | Anti-TNF | No increase in malignancy (including lymphoma). Increase in skin cancer (including melanoma) |
Dommasch et al. 2011 [125] | Plaque psoriasis, psoriatic arthritis | RCTs | Etanercept, Infliximab, adalimumab, certolizumab, golimumab | No increase in cancers for short-term use |
Askling et al. 2011 [126] | Any | RCTs | etanercept, infliximab, adalimumab | No increase in cancer with short-term use |
Campbell et al. [127] | RA | RCTs | Tocilizumab | No increase in risk of malignancy |
Lopez-Olivo et al. [128] | RA | RCTs | Adalimumab, Certolizumab, Etanercept, Golimumab, Infliximab, Abatacept, Anakinra, Rituximab, Tocilizumab | No increased risk of malignancy in comparison with DMARDs or placebo |
Moulis et al. 2012 [129] | RA | RCTs | Anti-TNF | No excess cancer risk in either per protocol or intention to treat analysis, non-significant trend for increased non-melanoma skin cancer |